Aesther Healthcare Acquisition said it has paid $1,050,000 into trust for a deadline extension on its business combination with Ocean Biomedical from Sept. 16 to Dec. 16.
Announced in August, the deal has an expected combined pro forma enterprise value of approximately $345 million, assuming no redemptions.
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries. Read more.
